Halozyme Therapeutics Inc Capital Reinvestment Ratio
Halozyme Therapeutics Inc capital reinvestment ratio. Halozyme Therapeutics Inc (HALO) has a Capital Reinvestment Ratio of 0.02x as of September 2025, meaning it reinvests 0% of its operating cash flow ($178.60 Million) in capital expenditures ($3.03 Million). Check total reinvestment intensity of Halozyme Therapeutics Inc to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Halozyme Therapeutics Inc (2006–2024)
Capital reinvestment ratio of Halozyme Therapeutics Inc from 2006 to 2024. This chart tracks Halozyme Therapeutics Inc's Capital Reinvestment Ratio across 7 annual periods. Also explore Halozyme Therapeutics Inc equity growth rate to track the company's year-over-year net asset growth rate.
Halozyme Therapeutics Inc Capital Reinvestment Ratio by Year (2006–2024)
Halozyme Therapeutics Inc capital reinvestment ratio by year from 2006 to 2024. For the full cash flow conversion analysis, see HALO operating cash flow.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.02x | $479.06 Million | $10.70 Million | ▼ -43.3% |
| 2023 | 0.04x | $388.57 Million | $15.29 Million | ▲ +96.5% |
| 2022 | 0.02x | $240.11 Million | $4.81 Million | ▲ +311.7% |
| 2021 | 0.00x | $299.44 Million | $1.46 Million | ▼ -89.2% |
| 2020 | 0.05x | $55.45 Million | $2.50 Million | ▲ +348.4% |
| 2017 | 0.01x | $134.05 Million | $1.35 Million | ▼ -80.5% |
| 2006 | 0.05x | $7.08 Million | $364.80K | — |